Absci Corp ABSI
Absci Corp (Nasdaq: ABSI) is a dermatology drug developer. Its lead program, ABS-201, is in Phase 1 for Androgenetic alopecia (persistent hair loss). Its next catalyst on record is ABS-201: Start Phase 2 in endometriosis (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ABS-201 — Start Phase 2 in endometriosis (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ABS-201 (anti-PRLR) | Androgenetic alopecia | antibody | Phase 1 |
| ABS-201 (anti-PRLR) | Endometriosis | antibody | Pre-clinical |
| ABS-202 | Undisclosed | antibody | Pre-clinical |
Recent results and decisions
- Jun 24, 2026positive Positive interim Phase 1 SAD data (n=32): well tolerated, no serious adverse events, estimated half-life of at least 65 days supporting 2-3 injections over six months.
Based on available interim pharmacokinetic data across all four SAD cohorts, including Day 56 follow-up in the lower-dose cohorts, half-life for ABS-201 is estimated to be at least 65 days.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.